Introduction

Molecular knowledge of the patient's leukemia critical, but this is now entered major league into the realm of therapy for AML. More targeted therapy in AML, younger adults, possibly more targeted therapy in the form of triplets for AML and older adults. In MDS, right now the big change is the impact of molecular on prognosis based on the release of the IPSSM.